← Leaderboards
Carston R. Wagner
University Of Minnesota Twin Cities
$9,182,483
Attributed
$9,182,483
Total exposure
6
Grants
5
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $1.2M · FY2007–25$2M$1.5M$1M$500K$0
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$9,182,483 · 6
By mechanism
R01$8,833,417 · 5
R21$349,066 · 1
Top collaborators
No co-investigators on record.
Most similar at University Of Minnesota Twin Cities
Same institution · by research overlap
- Vitaly A Polunovsky$3,087,622
- Jeffery J Schwinefus$189,260
- Daniel A Vallera$6,910,381
Others in their field
Top investigators on “In Vitro”
- David Heimbrook · Leidos Biomedical Research, Inc.$553,787,942
- Leonard Freedman · Leidos Biomedical Research, Inc.$310,441,779
- Mark S Klempner · Tufts Medical Center$128,021,180
- Florian Krammer · Icahn School Of Medicine At Mount Sinai$104,723,856
- Lynn Briscoe · Leidos Biomedical Research, Inc.$94,686,873
- Dennis R. Burton · Scripps Research Institute$79,204,175
Research focus
In VitroPharmaceutical PreparationsIn VivoSuccessCellsToxic EffectBaseTumorAntibodiesMethotrexateFluorophoreDihydrofolate ReductaseChimeric ProteinsMalignant NeoplasmsMolecularLigandsPre-ClinicalReportingBiodistributionDesignHeterogeneityRadiotracerFda ApprovedImmune
Grant awards (23)
Anchimerically Activatable Anti-Zika/Dengue ProTides$568,956
R01 · FY2025 · AI · contact PI
Anchimerically Activatable Anti-Zika/Dengue ProTides$568,956
R01 · FY2024 · AI · contact PI
Targeting Effector Immune cells to Cancer with Chemically Self-Assembled Nanorings (CSANs)$541,946
R01 · FY2024 · CA · contact PI
Anchimerically Activatable Anti-Zika/Dengue ProTides$568,956
R01 · FY2023 · AI · contact PI
Targeting Effector Immune cells to Cancer with Chemically Self-Assembled Nanorings (CSANs)$559,059
R01 · FY2023 · CA · contact PI
Anchimerically Activatable Anti-Zika/Dengue ProTides$568,956
R01 · FY2022 · AI · contact PI
Targeting Effector Immune cells to Cancer with Chemically Self-Assembled Nanorings (CSANs)$559,057
R01 · FY2022 · CA · contact PI
Anchimerically Activatable Anti-Zika/Dengue ProTides$670,946
R01 · FY2021 · AI · contact PI
Targeting Effector Immune cells to Cancer with Chemically Self-Assembled Nanorings (CSANs)$569,277
R01 · FY2021 · CA · contact PI
Targeting Effector Immune cells to Cancer with Chemically Self-Assembled Nanorings (CSANs)$544,030
R01 · FY2020 · CA · contact PI
Engineering Cell-Cell Interactions by Chemically Self-Assembled CARS$191,063
R21 · FY2016 · CA · contact PI
Engineering Cell-Cell Interactions by Chemically Self-Assembled CARS$158,003
R21 · FY2015 · CA · contact PI
Self-Assemblying Immunotherapeutic Nanorings$293,634
R01 · FY2011 · CA · contact PI
Self-Assemblying Immunotherapeutic Nanorings$302,786
R01 · FY2010 · CA · contact PI
Chemically Controlled Assembly of Therapuetic Protein Nanostrctures$281,808
R01 · FY2010 · CA · contact PI
Chemically Controlled Assembly of Therapuetic Protein Nanostrctures$314,382
R01 · FY2009 · CA · contact PI
Self-Assemblying Immunotherapeutic Nanorings$300,676
R01 · FY2009 · CA · contact PI
Chemically Controlled Assembly of Therapuetic Protein Nanostrctures$289,860
R01 · FY2008 · CA · contact PI
Self-Assemblying Immunotherapeutic Nanorings$285,990
R01 · FY2008 · CA · contact PI
Chemically Controlled Assembly of Therapuetic Protein Nanostrctures$348,922
R01 · FY2007 · CA · contact PI
STUDIES OF PHOSPHORAMIDATE PRONUCLEOTIDES$231,676
R01 · FY2003 · CA
STUDIES OF PHOSPHORAMIDATE PRONUCLEOTIDES$231,741
R01 · FY2002 · CA
STUDIES OF PHOSPHORAMIDATE PRONUCLEOTIDES$231,803
R01 · FY2001 · CA